KIM
HUMA icon

Karpus Investment Management’s Humacyte HUMA Stock Holding History

Karpus Investment Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,199
Closed -$144K – 313
2020
Q4 		$144K Buy
+14,199
New +$141K ﹤0.01% 216

Other funds holding HUMA

Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Karpus Investment Management's HUMA Position: Q1 2021 in Review

Karpus Investment Management sold out of Humacyte (HUMA) in Q1 2021, closing a stake of 14,199 shares — an estimated $144K sold.

Karpus Investment Management first reported a position in HUMA in Q4 2020 and held it in 1 quarter. The position peaked at $144K in Q4 2020. 23 funds tracked by Wall St. Rank hold HUMA as of Q1 2021.

  • Karpus Investment Management reported no remaining Humacyte position as of Q1 2021 after selling out during the quarter.
  • Karpus Investment Management sold 14,199 Humacyte shares in Q1 2021, an estimated $144K.
  • Karpus Investment Management first reported a position in Humacyte in Q4 2020 and held it in 1 quarter.
  • Karpus Investment Management's Humacyte position peaked at $144K in Q4 2020.
  • 23 funds tracked by Wall St. Rank held Humacyte as of Q1 2021.

Based on Karpus Investment Management's 13F filing for Q1 2021, filed 17 May 2021.